- Home
- CNR vs DNTH Comparison
CNR vs DNTH Comparison
Compare CNR & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNR | DNTH |
|---|---|---|
| Founded | 1864 | 2015 |
| Country | United States | United States |
| Employees | 4850 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNR | DNTH |
|---|---|---|
| Price | $88.66 | $90.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $111.50 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 668.3K | 425.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $7.26 | N/A |
| Revenue Next Year | $6.83 | $29.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $64.15 | $16.77 |
| 52 Week High | $114.80 | $96.50 |
Technical Indicators
Market Signals| Indicator | CNR | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 59.23 |
| Support Level | $83.89 | $81.16 |
| Resistance Level | $91.91 | $96.50 |
| Average True Range (ATR) | 3.26 | 4.45 |
| MACD | 1.09 | 0.25 |
| Stochastic Oscillator | 58.41 | 85.05 |
Price Performance
Historical ComparisonAbout CNR Core Natural Resources Inc.
Core Natural Resources Inc is a producer and exporter of metallurgical and thermal coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The activities of the company involves mining of thermal coal, power generation, and other related activities.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.